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Abstract
Background: Radical cystectomy is associated with high rates of perioperative morbidity. Robotic-assisted radical
cystectomy (RARC) is widely used today despite limited evidence for clinical superiority. The aim of this review was
to evaluate the effect of RARC compared to open radical cystectomy (ORC) on complications and secondary on
length of stay, time back to work and health-related quality of life (HRQoL).
Methods: The databases PubMed, The Cochrane Library, Embase and CINAHL were searched. A systematic review
according to the PRISMA guidelines and cumulative analysis was conducted. Randomized controlled trials (RCTs)
that examined RARC compared to ORC were included in this review. We assessed the quality of evidence using the
Cochrane Collaboration’s ‘Risk of bias’ tool and Grading of Recommendations Assessment, Development and
Evaluation approach. Data were extracted and analysed.
Results: The search retrieved 273 articles. Four RCTs were included involving overall 239 patients. The quality of the
evidence was of low to moderate quality. There was no significant difference between RARC and ORC in the
number of patients developing complications within 30 or 90 days postoperatively or in overall grade 3–5
complications within 30 or 90 days postoperatively. Types of complications differed between the RARC and the
ORC group. Likewise, length of stay and HRQoL at 3 and 6 months did not differ.
Conclusion: Our review presents evidence for RARC not being superior to ORC regarding complications, LOS and
HRQoL. High-quality studies with consistent registration of complications and patient-related outcomes are
warranted.
Systematic review registration: PROSPERO CRD42016038232
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Background
Worldwide, bladder cancer is the ninth most common
cancer with an estimated 429,800 new cases and 165,100
deaths in 2012. In the Western world, bladder cancer is
the fourth and ninth most common cancer in men and
women, respectively. Approximately, 30% of all newly
diagnosed patients present with muscle-invasive bladder
cancer (MIBC) [1, 2]. Radical cystectomy is the standard
treatment for patients with muscle-invasive bladder can-
cer and in selected patients with non-muscle-invasive
bladder cancer [1]. Patients undergoing radical cystec-
tomy are at high risk of perioperative morbidity with
about 60% experiencing at least one complication within
90 days after surgery [3, 4]. Open radical cystectomy
(ORC) with pelvic lymph node dissection is considered
the gold standard technique even though laparoscopic
radical cystectomy (LRC) has been possible since 2001
[5]. In 2003, robot-assisted radical cystectomy (RARC)
was introduced [6] and from 2004 to 2010, the utilization
of RARC has increased from <1 to 13% [7].
Minimally invasive surgery may reduce the surgical
stress response compared to open surgery [8], and
RARC seems to be advantageous in eldery people with
regard to complications [9]. In systematic reviews in-
cluding both randomized controlled trials (RCTs), retro-
spective and prospective comparative study designs,
RARC has similar oncological outcomes compared to
ORC [10, 11], however with lower perioperative blood
loss, fewer transfusions and shorter postoperative length
of stay (LOS). Further, the reviews conclude that, in ap-
propriately selected patients, RARC appears to be associ-
ated with significantly fewer total complications [4, 10,
12–14]. These results are not confirmed in randomized
controlled trials comparing RARC with ORC [15–18].
Complications have traditionally been seen as a sur-
rogate marker of quality in surgery [19], but little is
known about how complications influence postopera-
tive health-related quality of life (HRQoL). Today, in-
cluding patient-related outcomes when evaluating new
surgical techniques is therefore mandatory [20, 21]. If
RARC reduces complications rates, it could be ex-
pected that patients undergoing RARC would have a
shorter LOS and experience less negative impact postop-
eratively on HRQoL. The aim of this systematic review
was to evaluate the evidence from RCTs of robot-assisted
radical cystectomy (RARC) versus open radical cystec-
tomy (ORC) in regard to primarily complications, and
secondly LOS, HRQoL and time back to work or habitual
activity.
Methods
Protocol
Analysis methods and inclusion criteria for this systematic
review and meta-analysis were specified in advance and
documented in a protocol in compliance with the ‘Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses’ (PRISMA) Statement [22] (See Additional
file 1). The protocol was registered with the PROSPERO
database in April 2016 (CRD42016038232).
The primary outcome was the number of patients with
postoperative complications requiring treatment within
30 and 90 days. Complication rates were calculated
using the total number of patients randomized to ORC
and RARC respectively as the denominator. Secondary
outcomes were total number of postoperative complica-
tions within 30 and 90 days, type of complications, LOS,
time back to work or habitual activity and HRQoL as
measured by validated disease specific and/or generic
scales. Due to inconsistency in reporting of complica-
tions, it was not possible to perform a meta-analysis of
total number of complications. Instead, we performed a
meta-analysis of grade 3–5 complications.
Search strategy
The databases PubMed, The Cochrane Library,
Embase and CINAHL were initially searched August
2015 using the following search terms and strategy:
bladder cancer, open radical cystectomy, robot-
assisted radical cystectomy, postoperative complica-
tions, intraoperative complications, postoperative
pulmonary complications, postoperative cardiovascu-
lar complications, postoperative wound complication,
postoperative morbidity, postoperative mortality, post-
operative quality of life, postoperative length of stay,
postoperative time back to work and postoperative
cancer relapse (see Additional file 2).
The search was limited to patients aged 18 years or
more. No language or date limits were applied. A full
up-date of the searches was done September 2016.
Clinicaltrials.gov was searched to identify ongoing and
unpublished studies. Studies were checked for additional
relevant citations.
Criteria for considering studies for this review
We included RCTs comparing RARC to ORC and
reporting at least one outcome of interest. The re-
construction method for urinary diversion should
preferably be described as extra-corporeal or intra-
corporeal.
Definition of complications
To compare complications across studies in a system-
atic, objective and reproducible way, it is recom-
mended to use a standardized classification [19]. We
defined a postoperative complication as any complica-
tions needing treatment in accordance with the
“Clavien-Dindo” classification [23].
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Data extraction
Two authors (BTJ and SVL) reviewed all records re-
trieved from the search and included studies according
to the inclusion criteria. Discrepancies were resolved by
discussion. BTJ and SVL individually extracted data.
Discrepancies were solved by PT. We extracted the fol-
lowing study characteristics from the included studies:
author, country, year of publication, number of partici-
pants, types of surgery (ORC, RARC), intra-corporal or
extra-corporal urinary diversion, inclusion and exclu-
sion criteria, degree of follow-up and definition of
complications.
Furthermore, we extracted data on age, body mass
index (BMI), Charlsons comorbidity index (CCI) [24],
American Society of Anesthesiologists physical status
classification system (ASA) [25], gender, smoker, tumour
(pT and pN), total lymph nodes retrieved, surgical mar-
gins, type of urinary diversion, neoadjuvant chemother-
apy, complication rates within 30 days or 90 days post-
operatively, types of complications, length of stay,
HRQoL and time back to work/daily activity.
Assessment of reporting of complications
To assess the quality of reporting of complications after
urologic procedures using the Clavien-Dindo classifica-
tion, we used the data extraction form from the
European Association of Urology guideline “Reporting
and Grading of Complications after Urologic Surgical
Procedures” [19]. This form evaluates the number of
Martin et al. criteria for accurate and comprehensive
reporting of surgical complications [26] and the use of
Clavien-Dindo classification of complications. The
Clavien-Dindo classification includes five grades of
complications based on the main criterion of the inter-
vention needed to resolve the complication.
Risk of bias and quality assessment
Risk of bias was assessed using the Cochrane Collabora-
tion’s tool for assessing risk of bias [27]. This involved
assessment of sequence generation, allocation conceal-
ment, blinding of participants, personal and outcome,
incomplete outcome data, selective outcome reporting
and other sources of bias. The Grading of Recommen-
dations Assessment, Development and Evaluation
(GRADE) [28] approach was used to assess the quality
of the evidence. BTJ and SVL individually assessed risk
of bias and quality of evidence. Disagreements were re-
solved by TT.
Statistical analysis
For purposes of analysis, robot-assisted radical cystec-
tomy was considered the experimental group.
Cumulative analysis was conducted using Review
Manager (RevMan) [Computer Programme]. Version 5.3.
Copenhagen: The Nordic Cochrane Center, The Cochrane
Collaboration, 2014. Statistical heterogeneity was calcu-
lated using the I2 statistic, which describes the percentage
of the variability in effect estimates that is due to hetero-
geneity rather than sampling error.
For dichotomous outcomes, results were calculated
with the Mantel-Haenszel square method using the
‘fixed-effects’ meta-analytical technique to calculate risk
ratios (RR) and corresponding 95% confidence intervals
(CI). For continuous outcomes, the results were reported
as mean differences (MD) and corresponding 95% CIs.
Authors of the included studies were contacted for
additional information in case of missing data.
Results
The literature search retrieved 273 records. Twelve arti-
cles [15–18, 29–35] met the criteria for considering
studies. Of these, we included five articles covering four
studies (Fig. 1) [15–18]. Two articles [16, 29] were based
on the same trial but reported different outcomes: one
reported complications and one HRQoL.
Characteristics of included studies
Characteristics of included studies are summarized in
Table 1. The two reviewers who extracted data were in
total agreement. A total of 239 patient cases were ana-
lysed. Of these, 118 underwent ORC and 121 underwent
RARC. Approximately 80% of patients were male. No
studies reported the CCI score. ASA scores across
studies were comparable with the majority of patients
having ASA score 3. In Khan et al. [18], 75% of patients
had an ASA score of 2. In the RARC group, 70% of pa-
tients presented with tumour stage T2 or lower com-
pared to 63% in the ORC group. One study did not
report tumour stage [16]. Parekh et al. [16] did not de-
scribe the type of urinary diversion performed; the
remaining studies [15, 17, 18] performed extra-corporeal
urinary diversion (Table 1). No studies described adverse
events related to the surgical technique.
Characteristics of excluded studies
Of the potentially eligible studies, six were excluded, as
they were not RCTs; one study was a protocol for an on-
going study. Aboumarzouk et al. [31] compared 155
patients undergoing LRC or ORC retrospectively. Abou-
mohamed et al. [30] reported retrospective data from
patients undergoing radical cystectomy. Patients were
grouped based on surgical approach (ORC vs RARC)
and urinary diversion technique (extra-corporeal vs
intra-corporeal). Atmaca et al. [32] retrospectively com-
pared 42 open versus 32 intra-corporeal RARCs. Kahn
et al. [33] reported data from a prospective cohort study
of 158 patients from 2003 to 2008 undergoing ORC,
LRC or RARC. Ng et al. [34] used a prospective cohort
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design including 187 consecutive patients undergoing
either ORC or RARC. Finally, Niegisch et al. [35] pro-
spectively collected data on 64 patients undergoing
RARC and retrospectively compared these with 79
patients undergoing ORC. The on-going RAZOR
(randomized open vs robotic cystectomy) trial [36] is a
multi-institutional randomized clinical trial planning to
enrol at least 320 patients from 15 different institutions.
The aim of the RAZOR trial is to compare ORC with
RARC, pelvic lymph node dissection (PLND) and
urinary diversion in regard to oncological outcomes,
complications and HRQoL measures with a primary
endpoint of 2-year progression-free survival.
Assessment of risk of bias
Overall, the studies were assessed to be at moderate risk
of bias (Fig. 2). None of the studies had blinding of par-
ticipants or personnel. We consider it unlikely that this
influenced the primary outcome: perioperative complica-
tions. Therefore, the studies were assessed at low risk of
performance bias. Random sequence generation and al-
location concealment were assessed at high risk of bias
in Nix et al. [15] because the randomisation schema
was performed with five sequential patients undergoing
one surgical approach before subsequently altering sur-
gical technique. The study by Bochner et al. was
assessed to be at high risk of detection bias due to non-
blinding of outcome assessors [17]. The remaining
studies did not report if outcome assessors were
blinded and were therefore assessed to be at unclear
risk of detection bias. Outcome data were incomplete
in Bochner et al. [17]. Bochner et al. reported outcome
data on quality of life from 23 of 60 patients in the
RARC group and 34 of 58 patients in the ORC group.
Selective outcome reporting was identified in Khan et
al. [18] and Parekh et al. [16] with both reporting differ-
ent outcomes in the trial protocol and final article.
Other biases detected were incomplete reporting of com-
plications by Bochner et al. [17] and Parekh et al. [16] and
unclear reporting of complications in Nix et al. [15].
Fig. 1 PRISMA flow-chart literature search
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According to the GRADE assessment, the quality of
the evidence for complications was low and for LOS,
moderate (Table 2).
Complications
Three studies [15, 16, 18] classified complications ac-
cording to the Clavien-Dindo classification [37], and one
study [17] used the Memorial Sloan Kettering Cancer
Centre (MSKCC) modified Clavien-Dindo classification
[3], making comparison feasible. Reporting of complica-
tions was overall poor. One study [18] met eight of the
ten Martin criteria, and three studies [15–17] met five of
the ten Martin criteria. None of the included studies in-
cluded blood transfusion as a complication even though
this is a grade 2 complication according to the Clavien-
Dindo classification. One study [16] reported blood
transfusions separately. Two studies [16, 17] only reported
grade 2–5 complications. Khan et al. [18] reported grade
1–5 complications, and it is unclear if all grades were
assessed in Nix et al. [15] as they only reported median
and mean values for the Clavien-Dindo units.
The number of patients with complications within
30 days postoperatively ranged from 20 to 55% in the
RARC group and from 20 to 70% in the ORC group
and, within 90 days postoperatively, from 55 to 62% in
the RARC group and from 66 to 70% in the ORC group.
Review Manager only allows analysis of continuous out-
comes using means and standard deviations (SD). As
Parekh only reported the median, we used the calculated
mean and SD from the RARC Pasadena Consensus
Panel Review [4] in the meta-analysis of LOS. The meta-
analysis showed no statistically significant difference
Fig. 2 Risk of bias within studies
Table 1 Individual study characteristics
Reference No (ORC/RARC) Urinary diversion
method
Exclusion criteria Age, years
(ORC/RARC)
Mean (%) Matching
outcomes
Nix et al. 2010 [15]
USA
20/21 Extra-corporeal Not surgical candidates
Not allowing randomization
Preconceived preference for
ORC or RARC
69.2/67.4 (mean) 75.6 1,3,6
Parekh et al.a 2013 [16]
USA
20/20 Unclear Inability to give informed consent,
Multiple prior abd and pelvic
surgery Morbid obesity
Clinical T4 BC
LN positive BC or retroperitoneal LN
Preexisting condition precluding
safe pneumoperitoneum
Age <30 or >90
Pregnancy
64.5/69.5 (median) 85 1,3,6
Messer et al.a 2014 [29]
USA
5
Bochner et al. 2015 [17]
USA
58/60 Extra-corporeal Contraindication for Trendelenberg
Extensive prior abd surgery
65/ 66 (median) 78.8 2,3,5,7
Khan et al. 2016 [18]
UK
20/20 Extra-corporeal Previous pelvic radiation
T4 or M1
Contraindication for Trendelenberg
Extensive prior abd surgery
66.6/68.6 (mean) 87.5 1,2,3,5,6,7
Outcomes: 1: number of patients with complications within 30 days, 2: number of patients with complications within 90 days, 3: length of stay (days), 4: time back
to work, 5: quality of life, 6: number of grade 3–5 complications within 30 days, 7: number of grade 3–5 complications within 90 days
aSame population in Parekh and Messer
Lauridsen et al. Systematic Reviews  (2017) 6:150 Page 5 of 12
Ta
b
le
2
Su
m
m
ar
y
of
fin
di
ng
s
Q
ua
lit
y
as
se
ss
m
en
t
N
o.
of
pa
tie
nt
s
Ef
fe
ct
Q
ua
lit
y
Im
po
rt
an
ce
N
o.
of
st
ud
ie
s
St
ud
y
de
si
gn
Ri
sk
of
bi
as
In
co
ns
is
te
nc
y
In
di
re
ct
ne
ss
Im
pr
ec
is
io
n
O
th
er
co
ns
id
er
at
io
ns
O
pe
n
Ro
bo
t-
as
si
st
ed
ra
di
ca
lc
ys
te
ct
om
y
Re
la
tiv
e
(9
5%
C
I)
A
bs
ol
ut
e
(9
5%
C
I)
N
um
be
r
of
pa
tie
nt
s
w
ith
co
m
pl
ic
at
io
ns
w
ith
in
90
da
ys
2
Ra
nd
om
iz
ed
tr
ia
ls
Se
rio
us
a
N
ot
se
rio
us
N
ot
se
rio
us
Se
rio
us
b
N
on
e
48
/8
0
(6
0.
0%
)
52
/7
8
(6
6.
7%
)
RR
0.
90
(0
.7
1
to
1.
14
)
67
fe
w
er
pe
r
1.
00
0
(fr
om
93
m
or
e
to
19
3
fe
w
er
)
⨁
⨁
◯◯
Lo
w
G
ra
de
3–
5
co
m
pl
ic
at
io
ns
90
da
ys
(t
ot
al
co
m
pl
ic
at
io
ns
gr
ad
e
2–
5)
2
Ra
nd
om
iz
ed
tr
ia
ls
Se
rio
us
a
N
ot
se
rio
us
N
ot
se
rio
us
Se
rio
us
b
N
on
e
22
/5
8
(3
7.
9%
)
18
/5
1
(3
5.
3%
)
RR
1.
04
(0
.6
4
to
1.
71
)
14
m
or
e
pe
r
1.
00
0
(fr
om
12
7
fe
w
er
to
25
1
m
or
e)
⨁
⨁
◯◯
Lo
w
N
um
be
r
of
gr
ad
e
3–
5
co
m
pl
ic
at
io
ns
w
ith
in
30
da
ys
3
Ra
nd
om
iz
ed
tr
ia
ls
Se
rio
us
a
N
ot
se
rio
us
N
ot
se
rio
us
Se
rio
us
c
N
on
e
13
/2
8
(4
6.
4%
)
11
/2
3
(4
7.
8%
)
RR
1.
07
(0
.6
1
to
1.
87
)
33
m
or
e
pe
r
1.
00
0
(fr
om
18
7
fe
w
er
to
41
6
m
or
e)
⨁
⨁
◯◯
Lo
w
Le
ng
th
of
st
ay
3
Ra
nd
om
iz
ed
tr
ia
ls
N
ot
se
rio
us
N
ot
se
rio
us
N
ot
se
rio
us
Se
rio
us
d
N
on
e
10
0
98
–
M
D
0.
2
lo
w
er
(1
.5
4
lo
w
er
to
1.
14
hi
gh
er
)
⨁
⨁
⨁
◯
M
od
er
at
e
N
um
be
r
of
pa
tie
nt
s
w
ith
co
m
pl
ic
at
io
ns
w
ith
in
30
da
ys
3
Ra
nd
om
iz
ed
tr
ia
ls
Se
rio
us
a
N
ot
se
rio
us
N
ot
se
rio
us
Se
rio
us
c
N
on
e
23
/6
1
(3
7.
7%
)
29
/6
0
(4
8.
3%
)
RR
0.
78
(0
.5
3
to
1.
16
)
10
6
fe
w
er
pe
r
1.
00
0
(fr
om
77
m
or
e
to
22
7
fe
w
er
)
⨁
⨁
◯◯
Lo
w
Ti
m
e
ba
ck
to
w
or
k
or
ha
bi
tu
al
ac
tiv
ity
0
0
0
–
se
e
co
m
m
en
t
–
CI
co
nf
id
en
ce
in
te
rv
al
,R
R
ris
k
ra
tio
,M
D
m
ea
n
di
ff
er
en
ce
a I
nc
om
pl
et
e
re
po
rt
in
g
of
co
m
pl
ic
at
io
ns
ac
co
rd
in
g
to
th
e
C
la
vi
en
-D
in
do
C
la
ss
ifi
ca
tio
n
b
Sm
al
ls
am
pl
e
si
ze
in
on
e
of
th
e
st
ud
ie
s
c N
um
be
r
of
ev
en
ts
an
d
sa
m
pl
e
si
ze
s
ar
e
ve
ry
sm
al
l
d
Sm
al
ls
am
pl
e
si
ze
s
in
tw
o
of
th
e
st
ud
ie
s
Lauridsen et al. Systematic Reviews  (2017) 6:150 Page 6 of 12
between RARC and ORC in the number of patients de-
veloping complications within 30 days postoperatively,
RR 0.78 (95% CI, 0.53–1.16; p = 0.22) (Fig. 3 and Table 2).
Complication rates within 90 days postoperatively simi-
larly did not differ, RR 0.90 (95% CI, 0.71–1.14; p = 0.39)
(Fig. 3 and Table 2). The quality of the evidence was low
(Table 2).
Total number of postoperative complications within
30 days
Three studies [15, 16, 18] reported the total number of
complications within 30 days. In the RARC group, a
total of 23 events in 61 patients occurred and in the
ORC group, 29 events in 60 patients. Types of complica-
tions differed between the two groups with infections
and thromboembolic complications occurring more fre-
quently in the RARC group (Fig. 4). Sub-group analyses
according to types of complications showed no significant
differences. Infections: RR 1.36 (95% CI, 0.69–2.70;
p = 0.38); thromboembolic complications: RR 2.83 (95%
CI, 0.49–16.50; p = 0.25). There were fewer gastrointes-
tinal complications in the RARC group but not signifi-
cantly RR 0.50 (95% CI, 0.22–1.16; p = 0.11. Miscellaneous
complications in the open group included diagnosis of leu-
kaemia and dehydration and, in the robotic group,
evisceration.
Meta-analysis of grade 1–2 complications was not pos-
sible due to inconsistency in reporting. Parekh et al. [16]
only reported grade 2–5 complications. Meta-analysis of
grade 3–5 complications within 30 days postoperatively
showed no statistical difference between RARC and
ORC, RR 1.07 (95% CI,0.61–1.87; p = 0.82) (Fig. 5).
Total number of postoperative complications within
90 days
Two studies [17, 18] reported complications within
90 days postoperatively. In the RARC group, a total of
89 events occurred in 80 patients and, in the ORC
group, 97 events in 78 patients. Types of complications
differed less within 90 days postoperatively and still sub-
group analyses showed no significant differences. More
infections were seen in the RARC group; RR 1.32 (95%
CI 0.87–1.99; p = 0.19) as well as more cardiac compli-
cations; RR 1.21 (95% CI 0.54–2.72; p = 0.65). There
were fewer gastrointestinal complications in the RARC
group; RR 0.74 (95% CI 0.43–1.28; p = 0.28) and wound
complications occurred: RR 0.26 (95% CI 0.06–1.13;
p = 0.07). Miscellaneous complications were not speci-
fied [17] (Fig. 6). Bochner et al. [17] only reported grade
2–5 complications. Meta-analysis of grade 3–5 compli-
cations within 90 days showed no statistical difference
between RARC and ORC (Fig. 5). RR 1.04 (95% CI
0.64–1.71; p = 0.87).
Length of stay
Three studies with 198 patients reported data on LOS,
measured in days. Pooled estimates showed no statistical
difference between RARC and ORC, mean difference
(MD) −0.20 (95% CI −1.54, 1.14; p = 0.77) (Fig. 7). The
quality of the evidence was moderate (Table 2).
Fig. 3 Forest plot. Number of patients with complications within a 30 and b 90 days
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Time back to work
No studies assessed this outcome.
Quality of life
Three studies [17, 18, 29] assessed HRQoL in overall
198 patients. Khan et al. [18] measured HRQoL at
8 months postoperatively; Bochner et al. [17] at baseline
and after 3 and 6 months; Messer et al. [29] at baseline,
3, 6, 9 and 12 months. Data on HRQoL were available
from 114 of 198 patients (57.6%). Khan et al. [18] mea-
sured HRQoL using the Functional Assessment of
Cancer Therapy-Bladder (FACT-Bl) and the Functional
Assessment of Cancer-General (FACT-G) scale [38],
Messer et al. [29] used the Functional Assessment of
Cancer Therapy-Vanderbilt Cystectomy index scale [39];
Bochner et al. [17] used EORTC Quality of Life Ques-
tionnaire Core 30 (QLQ-C30) [40]. The FACT-G and
QLQ-C30 scales are both cancer generic instruments,
they are internationally validated and there is almost
complete agreement between the two instruments in the
nomenclature of the most important domains. However,
when trying to convert FACT-G scores to QLQ-C30
scores, the social domain shows serious inconsistencies
and is therefore not eligible for equating [41]. For this
Fig. 5 Forest plot. Grade 2–5 complications within a 30 and b 90 days
Fig. 4 Type of complications within 30 days
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reason, we refrained from meta-analysis of the HRQoL
outcome.
All three studies [17, 18, 29] assessing HLQoL found
no significant differences between RARC and ORC at 3
and 6 months with the exception of Messer et al. [29],
who found a 2.5-point lower score (FACT-VCI) in the
ORC group for physical well-being at 6 months. This
difference is not considered clinically relevant [29].
Discussion
We hypothesised that RARC would reduce postopera-
tive complications, LOS, time back to work and miti-
gate any negative impact of surgery on postoperative
HRQoL [4, 11–13]. Based on data from four RCTs
comparing RARC to ORC, robot-assisted radical cystec-
tomy did not reduce the rate of postoperative complica-
tions or LOS in patients with bladder cancer. Likewise,
postoperative HRQoL appeared to be similar in patients
undergoing RARC and ORC. Time back to work was not
assessed.
While the overall complication rates within 30 days
postoperatively resemble the rates reported in the review
by Novara et al. [4], their analyses showed a slightly
lower rate for any grade and grade 3 complications
within 90 days in favour of RARC. The absence of a dif-
ference in postoperative complications between RARC
and ORC in this review may be explained by the inclu-
sion of RCTs only, while former reviews [10–13] also
included studies comparing prospective patients under-
going RARC to retrospective ORC data. The quality of
the evidence in the present review was assessed to be
low for the primary outcome, the number of patients
developing complications postoperatively. Despite this,
we consider that our review contributes relevantly to
the evolving body of evidence within RARC, explicitly
due to the exclusive inclusion of RCTs.
In this review, all studies used the Clavien-Dindo clas-
sification of complications. Still comparison was difficult
because of unclear or incomplete reporting of complica-
tions. Judgement of complication status would also to
some degree have been subjective, with a risk of intra-
observer and inter-observer variation [42]. These factors
hamper comparison of complication rates between stud-
ies even when the same classification is used and the
strength of the conclusions that can be drawn from this
review.
Radical cystectomy is a complex procedure, and the
surgical technique per se may not influence the risk of
Fig. 6 Type of complications within 90 days
Fig. 7 Forest plot. Length of stay (days)
Lauridsen et al. Systematic Reviews  (2017) 6:150 Page 9 of 12
postoperative complications as much as other identified
predictors. Former reviews have for example identified
ASA score and age at surgery as non-modifiable predic-
tors for grade 3–5 complications [3, 4, 43]. In this re-
view, the mean or median age was 66–69 in the RARC
group and 65–69 in the ORC group. ASA scores were
also comparable across the RARC and ORC groups,
which may partially explain the similar postoperative
complication rates in the two groups.
In this systematic review, all urinary diversions were
performed extra-corporeally (ECUD) which may have in-
fluenced the outcomes and diminished the advantages of
the robotic technique. This may be ascribed to the fact
that the surgical stress response associated with extra-
corporeal diversion is similar to the surgical stress re-
sponse caused by an open approach [21]. Two studies
[44, 45] comparing postoperative complications in pa-
tients undergoing ECUD and intra-corporeal urinary di-
version (ICUD) found a trend in favour of ICUD. Ahmed
et al. [44] compared 768 patients who had ECUD to 167
patients who had ICUD and found no statistically signifi-
cant difference in complication rates within 30 days (43%
in the ECUD group vs 35% in the ICUD group; p = 0.07).
The authors estimated that about 18% of patients under-
going RARC had ICUD performed [44].
Several reviews [4, 11–13] have reported shorter LOS
after RARC compared to ORC. This may be attributed
to their findings of fewer complications in the RARC
group. In this review, we did not identify a significant
difference in LOS, possibly reflecting the identical com-
plication rates in the RARC and in the ORC groups.
Mean LOS ranged from 5 to 12 days in the robotic
group and from 6 to 14 in the open group. The longest
LOS was seen in the most recent study [18] and may be
explained by different discharge criteria more than from
surgical technique.
To the best of our knowledge, this is the first systematic
review addressing both the inconsistencies in reporting of
complications in studies comparing RARC and ORC and
the quality of the evidence according to the GRADE cri-
teria and the potential limitations this consequently infers
on the conclusions that can be drawn. We found no
differences between the RARC and ORC groups in com-
plications, LOS and HRQoL at 3 or 6 months. Quality of
life is a key component of the value of any treatment and
should be considered in discussions when a new surgical
technique is implemented. At present, we have insufficient
data on HRQoL following RARC and ORC to determine
whether RARC may be superior to ORC in regard to this
outcome. Results from the RAZOR study [36] may give
new insight in this field. Likewise, we lack data on time
back to work or habitual activity as none of the studies ad-
dressed these outcomes. During the submission process,
two additional reviews of the same four RCTs were
published [46, 47]. Both reviews found results for peri-
operative complications similar to ours. Moreover, they
found evidence for significantly reduced perioperative
blood loss and a longer operating time in the RARC
group.
Limitations and strengths
A major limitation of this review is the few RCTs and
cases. Furthermore, included studies were small; however,
they had a relatively high frequency of complications.
Only two studies [17, 18] reported power calculations for
detecting clinically relevant differences in postoperative
complications between the RARC and ORC groups. The
lack of statistical power impedes firm conclusions regard-
ing the potential superiority of RARC to ORC. The
incomplete reporting of complications is a limitation. Fu-
ture studies should observe guidelines for assessing and
reporting of complications, for example the EAU guideline
“Guidelines on Reporting and Grading of Complications
after Urologic Surgical Procedures” [19] to ensure stan-
dardized, uniform and valid data acquisition. The inclu-
sion of only RCTs and the absence of statistical
heterogeneity between studies strengthen the conclusions
that can be drawn from this review.
Conclusion
Based on low to moderate quality evidence from four
RCTs at moderate risk of bias, patients with bladder
cancer undergoing RARC did not develop fewer compli-
cations or have shorter length of stay compared to pa-
tients undergoing ORC. There is a need for high-quality
studies with consistent registration of complications ac-
cording to guidelines. Knowledge of patients’ experience
of HRQoL postoperatively and time back to work or
habitual activity is warranted as there is a sparsity of
evidence for these outcomes after RARC and ORC.
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